1-deoxynojirimycin has been researched along with Obesity in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.90) | 18.7374 |
| 1990's | 5 (17.24) | 18.2507 |
| 2000's | 6 (20.69) | 29.6817 |
| 2010's | 14 (48.28) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Aerts, JM; Bijl, N; Boot, RG; Copeland, D; Ghauharali, K; Groen, AK; Groener, JE; Liu, H; Meijer, AJ; O'Shea, TJ; Ottenhoff, R; Overkleeft, HS; Song, H; van den Berg, RJ; van der Marel, GA; van Eijk, M; Wennekes, T; Yew, N | 1 |
| Aerts, JMFG; Boot, R; Foppen, E; Herrera Moro Chao, D; Jansen, K; Kalsbeek, A; Kooijman, S; Marques, AR; Mergen, C; Mirzaian, M; Ottenhoff, R; Overkleeft, H; Parlevliet, ET; Rensen, PCN; Scheij, S; Seeley, RJ; Tschöp, MH; van Eijk, M; van Roomen, C; Verhoek, M; Wang, D; Wang, Y; Yi, CX | 1 |
| Aramwit, P; Rasmi, Y; Supasyndh, O; Thaipitakwong, T | 1 |
| Honda, Y; Imajo, K; Iwaki, M; Kessoku, T; Kobayashi, T; Nagashima, Y; Nakajima, A; Nogami, A; Ogawa, Y; Ozaki, A; Saito, S; Tomeno, W; Yoneda, M | 1 |
| Chen, JJ; Chen, JL; Chen, QY; Jin, P; Li, AN; Li, QQ; Liao, ZM; Wang, KS; Yang, ZC; Zeng, GY | 1 |
| Kikuchi, I; Kimura, T; Miyazawa, T; Nakagawa, K; Tsuduki, T | 1 |
| Fujita, Y; Hiraga, H; Kikuchi, O; Kim, HJ; Kitamura, T; Kitazumi, T; Kobayashi, M; Maruyama, J; Nakagawa, Y; Okamatsu-Ogura, Y; Saito, M; Sasaki, T; Shibata, H; Shimpuku, M; Susanti, VY; Yokota-Hashimoto, H | 1 |
| Chung, JH; Do, HJ; Hwang, JW; Kim, OY; Lee, JY; Shin, MJ | 1 |
| Hiraga, H; Kitamura, T; Sasaki, T; Yokota-Hashimoto, H | 1 |
| Arakawa, M; Ebato, C; Fujitani, Y; Hirose, T; Kawamori, R; Mita, T; Shimizu, T; Watada, H | 1 |
| Aerts, JM; Aten, J; Bijl, N; Boot, RG; Claessen, N; Groen, AK; Langeveld, M; Moerland, PD; Ottenhoff, R; Sokolović, M; van Eijk, M; van Roomen, CP; Vrins, C | 1 |
| Aerts, JM; Bijl, N; Bijland, S; Groen, AK; Houben-Weerts, JH; Houten, SM; Langeveld, M; Ottenhoff, R; Romijn, JA; van den Berg, SA; van Dijk, KW; van Roomen, CP; Voshol, PJ | 1 |
| Aerts, JM; Aten, J; Bietrix, FM; Bijl, N; Boot, RG; Dekker, N; Groen, AK; Groener, J; Langeveld, M; Lombardo, E; Ottenhoff, R; Overkleeft, HS; Serlie, M; van Eijk, M; van Roomen, C; Wennekes, T | 1 |
| Fujita, H; Hosoba, M; Morii, T; Narita, T; Sato, T; Tsukiyama, K; Yamada, Y; Yamashita, R; Yokoyama, H | 1 |
| Kaku, H; Tajiri, Y; Yamada, K | 1 |
| Higa, M; Masuzaki, H; Sata, M; Shimabukuro, M; Yamakawa, K | 1 |
| Fuchigami, M; Furuta, S; Hamada, Y; Nagasaki, H; Nakamura, J; Oiso, Y; Seino, Y | 1 |
| Bhatia, G; Chaturvedi, U; Saxena, JK; Shrivastava, A; Singh, SV | 1 |
| Horowitz, M; Lee, A; Morley, JE; Patrick, P; Wishart, J | 1 |
| Fischer, S; Hanefeld, M | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Butters, TD; Dwek, RA; Platt, FM; Priestman, DA; van der Spoel, AC | 1 |
| DeBouno, JF; Michaelis, OE; Tulp, OL | 1 |
| Axen, KV; Li, X; Sclafani, A | 1 |
| Dolphin, PJ; Graham, SE; Russell, JC | 1 |
| DeBouno, JF; Michaelis, OE; Szepesi, B; Tulp, OL | 1 |
| Fujioka, S; Keno, Y; Kobatake, T; Matsuzawa, Y; Tarui, S; Tokunaga, K | 1 |
| Federlin, K; Hillebrand, I; Laube, H | 1 |
| Luger, A; Röggla, G; Schernthaner, G; Schnack, C | 1 |
2 review(s) available for 1-deoxynojirimycin and Obesity
| Article | Year |
|---|---|
Glycosphingolipids and insulin resistance.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction | 2011 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
7 trial(s) available for 1-deoxynojirimycin and Obesity
| Article | Year |
|---|---|
A randomized controlled study of dose-finding, efficacy, and safety of mulberry leaves on glycemic profiles in obese persons with borderline diabetes.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Blood Glucose; Enzyme Inhibitors; Female; Healthy Volunteers; Humans; Male; Morus; Obesity; Plant Leaves; Postprandial Period; Prediabetic State; Thailand; Young Adult | 2020 |
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Topics: 1-Deoxynojirimycin; Acarbose; Adult; Blood Glucose; Cross-Over Studies; Enzyme Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Insulin; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Lipoprotein Lipase; Male; Middle Aged; Obesity; Postprandial Period; Single-Blind Method; Vascular Cell Adhesion Molecule-1; Viscera | 2008 |
Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Asian People; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Inositol; Male; Middle Aged; Obesity; Postprandial Period | 2012 |
Anorexigenic effects of miglitol in concert with the alterations of gut hormone secretion and gastric emptying in healthy subjects.
Topics: 1-Deoxynojirimycin; Adult; Appetite; Appetite Depressants; Female; Gastric Emptying; Ghrelin; Glucagon-Like Peptide 1; Humans; Male; Obesity; Peptide YY; Young Adult | 2012 |
Miglitol, α-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: a randomized comparable study.
Topics: 1-Deoxynojirimycin; Adult; alpha-Glucosidases; Cardiovascular Diseases; Female; Glycoside Hydrolase Inhibitors; Humans; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; Obesity; Risk Factors; Risk Reduction Behavior | 2013 |
The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Topics: 1-Deoxynojirimycin; Adult; Aged; Appetite; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Middle Aged; Obesity; Peptide Fragments; Postprandial Period; Protein Precursors | 2002 |
Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Middle Aged; Obesity; Pancreatic Hormones | 1986 |
20 other study(ies) available for 1-deoxynojirimycin and Obesity
| Article | Year |
|---|---|
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
Topics: Absorption; Animals; Blood Glucose; Carbohydrate Metabolism; Glycated Hemoglobin; Glycosphingolipids; Imino Sugars; Mice; Mice, Obese; Obesity; Rats; Rats, Zucker; Structure-Activity Relationship; Viscera | 2010 |
The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1.
Topics: 1-Deoxynojirimycin; Adamantane; Adipose Tissue, Brown; Animals; Brain; Glucagon-Like Peptide 1; Glucose; Male; Mice; Mice, Inbred C57BL; Obesity; Rats; Rats, Wistar; Satiation; Signal Transduction | 2019 |
Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice.
Topics: 1-Deoxynojirimycin; Animals; Chronic Disease; Diet, High-Fat; Dietary Sucrose; Disease Models, Animal; Gastrointestinal Absorption; Gene Expression; Glucose; Insulin Resistance; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Patient Acuity; RNA, Messenger; Sodium-Glucose Transporter 1; Sorbitol | 2021 |
Alpha-glucosidase inhibitor 1-Deoxynojirimycin promotes beige remodeling of 3T3-L1 preadipocytes via activating AMPK.
Topics: 1-Deoxynojirimycin; 3T3-L1 Cells; Adipocytes; Adipocytes, Beige; Adipogenesis; AMP-Activated Protein Kinases; Animals; Cell Differentiation; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Mice; Obesity; Up-Regulation | 2019 |
Intake of mulberry 1-deoxynojirimycin prevents diet-induced obesity through increases in adiponectin in mice.
Topics: 1-Deoxynojirimycin; Adiponectin; Adipose Tissue; Animals; Dietary Fats; Humans; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Morus; Obesity | 2013 |
Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates.
Topics: 1-Deoxynojirimycin; Acarbose; Adipocytes, Brown; Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Cell Line; Diet, High-Fat; Dietary Carbohydrates; Digestion; Eating; Energy Metabolism; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Obesity; Oxygen Consumption; Receptors, Adrenergic, beta; Signal Transduction | 2013 |
1-deoxynojirimycin isolated from Bacillus subtilis improves hepatic lipid metabolism and mitochondrial function in high-fat-fed mice.
Topics: 1-Deoxynojirimycin; Acetyl-CoA Carboxylase; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agents; Bacillus subtilis; Body Weight; CCAAT-Enhancer-Binding Proteins; CD36 Antigens; Diet, High-Fat; Dietary Supplements; Energy Intake; Fatty Acid Synthases; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Obesity; Organ Size; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phosphorylation; Transcription Factors | 2015 |
Miglitol protects against age-dependent weight gain in mice: A potential role of increased UCP1 content in brown adipose tissue.
Topics: 1-Deoxynojirimycin; Adipose Tissue, Brown; Adiposity; Aging; Animals; Diet; Energy Metabolism; Gene Expression; Hypoglycemic Agents; Ion Channels; Male; Mice; Mice, Inbred C57BL; Mitochondrial Proteins; Motor Activity; Obesity; Oxygen Consumption; Uncoupling Protein 1; Weight Gain | 2015 |
Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Disease Models, Animal; Fatty Liver; Glucose; Glycosphingolipids; Homeostasis; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Triglycerides | 2009 |
Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation.
Topics: 1-Deoxynojirimycin; Adamantane; Adipose Tissue; Animals; Body Weight; Carbohydrate Metabolism; Carnitine O-Palmitoyltransferase; Eating; Ghrelin; Glucose; Imino Sugars; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Oxidation-Reduction; Peptide YY; Triglycerides; Up-Regulation; Weight Gain | 2012 |
The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
Topics: 1-Deoxynojirimycin; Animals; Bile Acids and Salts; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Obesity; Rats; Rats, Wistar | 2013 |
Lipid lowering and antioxidant effect of miglitol in triton treated hyperlipidemic and high fat diet induced obese rats.
Topics: 1-Deoxynojirimycin; 3T3-L1 Cells; Adipogenesis; Animals; Antioxidants; Body Weight; Diet, High-Fat; Eating; Hyperlipidemias; Hypoglycemic Agents; Lipids; Liver; Male; Mice; Obesity; Polyethylene Glycols; Rats | 2013 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
N-butyldeoxynojirimycin causes weight loss as a result of appetite suppression in lean and obese mice.
Topics: 1-Deoxynojirimycin; Adipose Tissue; Animals; Appetite Regulation; Enzyme Inhibitors; Leptin; Mice; Mice, Obese; Obesity; Weight Loss | 2008 |
The effects of the intestinal glucosidase inhibitory BAY M 1099 (miglitol) on glycemic status of obese-diabetic rats.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Eating; Glucosamine; Glycoside Hydrolase Inhibitors; Imino Pyranoses; Male; Obesity; Rats; Rats, Inbred SHR | 1993 |
Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
Topics: 1-Deoxynojirimycin; Animal Feed; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glucosamine; Glucose; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Secretion; Islets of Langerhans; Obesity; Rats; Rats, Sprague-Dawley; Ventromedial Hypothalamic Nucleus | 1999 |
Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099).
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Body Weight; Disease Models, Animal; Eating; Enzyme Inhibitors; Glucosamine; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Lipids; Male; Obesity; Postprandial Period; Rats | 1999 |
The effects of low-dose Bay-m-1099 (Miglitol) on serum lipids and liver enzyme activity of obese and obese-diabetic corpulent rats.
Topics: 1-Deoxynojirimycin; Adipose Tissue; Animals; Blood Glucose; Blood Proteins; Diabetes Mellitus; Glucokinase; Glucosamine; Glucosephosphate Dehydrogenase; Glycoside Hydrolase Inhibitors; Imino Pyranoses; Insulin; Lipids; Liver; Obesity; Phenotype; Rats; Weight Gain | 1991 |
Treatment of visceral fat obesity.
Topics: 1-Deoxynojirimycin; Adipose Tissue; Animals; Cyclohexanols; Diet, Reducing; Disaccharides; Exercise Therapy; Glycoside Hydrolase Inhibitors; Humans; Obesity; Skin; Sucrase; Viscera | 1991 |
Effect of alpha-inhibitors on blood glucose and insulin levels.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Middle Aged; Obesity; Reference Values; Trisaccharides | 1988 |